-
Mashup Score: 1Registration - 3 year(s) ago
Tue, Jun 8, 2021 5:00 PM – 6:00 PM UTC Join VJHemOnc for an exclusive Myeloma Session, where patient advocates discuss their experiences. We are delighted to be joined by…
Source: register.gotowebinar.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 8CAR-T and BiTEs – which targets belong in clinical practice? - 3 year(s) ago
T-cell directed immune therapies, including chimeric antigen receptor (CAR)-modified T-cells and bispecific T-cell engagers (BiTEs) have revolutionized the treatment of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CART and BiTEs – which targets belong in clinical practice? Hear from @DrGarethMorgan1 of @nyulangone: https://t.co/xoXix90guR @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM #ImmunoOnc
-
-
Mashup Score: 0Registration - 3 year(s) ago
Tue, Jun 8, 2021 5:00 PM – 6:00 PM UTC Join VJHemOnc for an exclusive Myeloma Session, where patient advocates discuss their experiences. We are delighted to be joined by…
Source: register.gotowebinar.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Join us for the next #Myeloma Session with @VJHemOnc! @Mohty_EBMT tells us what to look forward to at the post-#COMy21 myeloma session featuring patients advocates! 👨⚕️👩⚕️ 💥 Register now: https://t.co/ZC1Xpyjjc0 💥 #VJSessions #MyelomaSessions #MMsm #MultipleMyeloma https://t.co/lSl2QxnGlC
-
-
Mashup Score: 2
Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) is a single cell sequencing method that enables detailed immunophenotypic profiling…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CITE-seq analysis predicts response to #CART and bispecifics in #Myeloma! Paola Neri of @UCalgaryMed shares details on immunophenotypic profiling of patient’s T-cells to predict response: https://t.co/wc91N18LSr @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM #ImmunoOnc
-
-
Mashup Score: 1
The FDA approval of idecabtagene-vicleucel for the treatment of relapsed/refractory (R/R) multiple myeloma represents the first cell-based gene therapy approval…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #CART field in #Myeloma continues to grow & evolve @TomBmt133 (@UCSFCancer) talks on bringing #CART therapy to a frontline setting in #Myeloma: https://t.co/96Vz8vL3nR @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM #ImmunoOnc
-
-
Mashup Score: 2Can we replace chemotherapy in the myeloma treatment space? - 3 year(s) ago
Saad Usmani, MD, University of North Carolina School of Medicine, Chapel Hill, NC, shares his predictions on how the myeloma…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Can we replace chemotherapy in the #Myeloma treatment space?🤔 @szusmani (@UNC_SOM) shares his predictions on how the myeloma treatment space will develop in the coming years: https://t.co/Dz2oB7K1ob @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM
-
-
Mashup Score: 0BET and CBP/EP300: emerging epigenetic therapeutic targets for the treatment of myeloma - 3 year(s) ago
Disruption of epigenetic processes contributes to disease pathogenesis in multiple myeloma through altered gene function. Proteins involved in these epigenetic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BET and CBP/EP300: emerging epigenetic therapeutic targets for the treatment of #Myeloma @DrGarethMorgan1 of @nyulangone explains why epigenetic processes are under investigation in myeloma: https://t.co/1UchiWEKRq @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM #CaxTx
-
-
Mashup Score: 0How I treat patients with MRD after transplantation - 3 year(s) ago
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke with Michele Cavo, University of Bologna, Bologna, IT. He discusses how to treat patients with minimal residual disease (MRD) after transplantation.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During #COMy21, @MM_Hub spoke with Michele Cavo, @UniboMagazine. He discusses how to treat patients with minimal residual disease (MRD) after transplantation. 👀Watch the interview here: 👉 https://t.co/xFzTDu1XJ9 👈 #mmsm #MultipleMyeloma https://t.co/cc4opPS37x
-
-
Mashup Score: 0AMG 420 and AMG 701 in R/R myeloma - 3 year(s) ago
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the use of the bispecific T-cell engagers (BiTEs), AMG 420…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
AMG 420 and AMG 701 in R/R #Myeloma w/ @H_Einsele of @Uni_WUE: https://t.co/xn8JF0pAM1 @COMyCongress #COMy21 #HemOnc #MultipleMyeloma #MMSM #ImmunoOnc #TrialUpdate #CTSM
-
-
Mashup Score: 4Registration - 3 year(s) ago
Tue, Jun 8, 2021 5:00 PM – 6:00 PM UTC Join VJHemOnc for an exclusive Myeloma Session, where patient advocates discuss their experiences. We are delighted to be joined by…
Source: register.gotowebinar.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Our post-#COMy21 #Myeloma patients session will take place on June 8 at 7pm CEST/6pm BST/1pm EDT! w/@Mohty_EBMT, @sarah_0875, @JackMAiello, @MyelomaTeacher and @IMFjimMYELOMA 👩⚕👨⚕ Register here: https://t.co/6lEXtvLPns @VJHemOnc #VJSessions #MyelomaSessions #MMsm https://t.co/tXFocg1U5Y
-
📣 There’s still time to register for the post-#COMy21 roundtable discussion on patient perspectives in myeloma 👩⚕👨⚕ 📅 Tuesday June 8 @ 7pm CEST/6pm BST/1pm EDT 💥 Register here: https://t.co/eYa2vg0YOq 💥 @VJHemOnc #VJSessions #MyelomaSessions #MMsm #MultipleMyeloma https://t.co/X9cjrE6Fqh